Spinal Cord Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

September 2022 | 180 pages | ID: S89AAAA8C6A4EN
Global Markets Direct

Abstracts

Spinal Cord Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Drugs In Development, 2022, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 10, 10, 2, 40, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 2 and 12 molecules, respectively.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Spinal Cord Injury - Overview
Spinal Cord Injury - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Spinal Cord Injury - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Spinal Cord Injury - Companies Involved in Therapeutics Development
Spinal Cord Injury - Drug Profiles
Spinal Cord Injury - Dormant Projects
Spinal Cord Injury - Discontinued Products
Spinal Cord Injury - Product Development Milestones
Featured News & Press Releases
Sep 17, 2022: NervGen Pharma presenting at upcoming Military Health System Research Symposium and the 61st International Spinal Cord Society Annual Scientific Meeting
May 20, 2022: Birmingham research brings hope for spinal cord injury treatment
May 18, 2022: NervGen hosting ppanel discussion with leading experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)
May 12, 2022: NervGen Pharma receives approval to proceed to the final dose cohort in phase 1 clinical trial of NVG-291
Mar 31, 2022: NervGen presenting interim phase 1 clinical trial data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting
Mar 23, 2022: NervGen Pharma to present at 2022 virtual growth conference presented by Maxim Group
Mar 15, 2022: NervGen Pharma receives approval from Safety Review Committee to proceed to second cohort in multiple ascending dose portion of phase 1 clinical trial of NVG-291
Jan 10, 2022: NervGen Pharma announces intent to conduct groundbreaking spinal cord injury clinical trial in exclusive partnership with Shirley Ryan AbilityLab, 1-Ranked Hospital in Physical Medicine & Rehabilitation
Dec 22, 2021: NervGen Pharma receives ethics board approval for multiple ascending dose portion of NVG-291 phase 1 trial
Nov 04, 2021: NervGen presents additional phase 1 clinical trial data for NVG-291 at Neuroscience 2021 / safety review committee provides recommendation to proceed to multiple ascending dose portion of the trial
Oct 27, 2021: NervGen Pharma announces spinal cord injury clinical advisory board
Oct 18, 2021: NervGen presents interim phase 1 clinical trial data for NVG-291 at the American Neurological Association 146th Annual Meeting / NVG-291 demonstrated to be well tolerated along with a favorable pharmacokinetic profile
Sep 27, 2021: NervGen Pharma partners with Imeka to use novel neuroimaging technology in clinical trials
Sep 12, 2021: NervGen Pharma presenting at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 08, 2021: Phase 2 Trial of MT-3921 initiated for treatment of spinal cord injury
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Spinal Cord Injury, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Companies, 2022 (Contd..3)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Spinal Cord Injury - Dormant Projects, 2022
Spinal Cord Injury - Dormant Projects, 2022 (Contd..1)
Spinal Cord Injury - Dormant Projects, 2022 (Contd..2)
Spinal Cord Injury - Dormant Projects, 2022 (Contd..3)
Spinal Cord Injury - Dormant Projects, 2022 (Contd..4)
Spinal Cord Injury - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Spinal Cord Injury, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022